Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 immunotherapy for prostate cancer

Date

09 Oct 2016

Session

Poster display

Presenters

Scott Tagawa

Citation

Annals of Oncology (2016) 27 (6): 243-265. 10.1093/annonc/mdw372

Authors

S.T. Tagawa1, D. Scherr2, J. Batra2, Y. Jhanwar3, B. Robinson4, D. Nanus1, H. Beltran1, A. Molina1, P. Christos5, N. Bander2

Author affiliations

  • 1 Division Of Hematology & Medical Oncology, Weill Cornell Medical College, 10065 - New York/US
  • 2 Urology, Weill Cornell Medical College, 10065 - New York/US
  • 3 Radiology, Weill Cornell Medical College, 10065 - New York/US
  • 4 Pathology, Weill Cornell Medical College, 10065 - New York/US
  • 5 Division Of Biostatistics And Epidemiology, Weill Cornell Medical College, 10065 - New York/US
More

Resources

Abstract 4218

Background

PSMA is a highly restricted cell-surface protein whose expression is increased with grade, stage, and attenuated AR signaling. J591 is a mAb against the external domain of PSMA and has demonstrated safety in numerous human-studies with anti-tumor activity when radiolabeled and conjugated with drug, with PSA and CTC declines. It was originally engineered to elicit antibody-dependent cellular cytotoxicity (ADCC) and we have made 2 important options leading to the current prospective clinical trials. First, studies of 177Lu-J591 have demonstrated >90% CTC control. While initially thought to represent delivery of 177Lu into CTCs and tumors, we retrospectively observed 4 of 7 patients with CTC count decline with a small amount (20 mg) of J591 without an effector molecule when used for imaging. Second, we analyzed long-term follow up from a 2001 study in men with biochemically recurrent or metastatic CRPC where men received unlabeled J591 plus low dose IL-2. Using validated nomograms, pen with biochemical relapse survived a median on 87 months longer than predicted without metastatic disease and in the pre-docetaxel era, men with mCRPC lived a median of 28.5 months longer than predicted. Based upon the preliminary data pointing towards CTC clearance and long-term survival, we have launched 2 prospective clinical trials.

Trial design

In study 1 [NCT02552394], men with progressive mCRPC by PCWG2 criteria and unfavorable CTC counts (>5 by CellSearch) on a stable hormonal regimen will receive a single dose of J591 in dose de-escalation cohorts followed by an expansion cohort at the lowest dose level with >4 of 6 men responding (i.e. achieve CTC 4 of the initial 10 men achieve the primary endpoint of peri-tumoral inflammation, an additional 20 will be treated. Additional endpoints include ADCC and lymphocyte subset analysis. Both studies include 89Zr-J591 PET/CT (pre- and post-therapy for the mCRPC CTC study and pre-op for the prostatectomy study). Each study has received IRB and FDA clearance and have begun enrollment.

Clinical trial identification

Clinicaltrials.gov NCT02552394 and NCT02693860

Legal entity responsible for the study

N/A

Funding

Weill Cornell Medicine

Disclosure

N. Bander: Patent holder for J591.

All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings